4D Molecular Therapeutics, Inc. (FDMT) — Stock Score Summary

4D Molecular Therapeutics, Inc. (FDMT) has a MoatMap StockRank of 35/100 based on Quality (33/100), Value (43/100), and Momentum (47/100) factor scores. The current signal is SELL. 4D Molecular Therapeutics is a clinical-stage gene therapy company. It operates as a high-beta biotech play without the structural pricing power or validated manufacturing scale of a high-moat CDMO, failing our fundamental quality screens.

4D Molecular Therapeutics is a clinical-stage gene therapy company developing precision AAV vector-based therapeutics for genetic diseases across ophthalmology, pulmonology, and cardiology. Its proprietary Therapeutic Vector Evolution platform allows for the engineering of optimized AAV vectors with enhanced tropism, immunogenicity, and efficiency. This positions FDMT as a specialized innovator in the gene therapy space, aiming to overcome limitations of conventional gene delivery.

Key Financial Metrics

Price$9.53
Market Cap$469M
P/E (Forward)-2.34
Price/Book1.01
Return on Equity-34.9%
Return on Invested Capital-30.5%
Debt/Equity4.54
Gross Margin-145.7%
Operating Margin-2416.1%
Revenue Growth21664.3%
Free Cash Flow$-69M

4D Molecular Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is 4D Molecular Therapeutics, Inc.’s (FDMT) StockRank?
MoatMap’s StockRank for 4D Molecular Therapeutics, Inc. (FDMT) is 35/100, with a Sell signal. It is a composite of Quality (33), Value (43), and Momentum (47) factor ranks across MoatMap’s 19,000+ stock universe.
Does 4D Molecular Therapeutics, Inc. have an economic moat?
4D Molecular Therapeutics, Inc. (FDMT) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is 4D Molecular Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for 4D Molecular Therapeutics, Inc. (FDMT) is Sell, based on a StockRank of 35/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is 4D Molecular Therapeutics, Inc. in?
4D Molecular Therapeutics, Inc. (FDMT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksFDMT deep dive reportAI ChampionsHow we score stocksSense-check another stock